Carcinoma in situ of larynx

CD2_INSITU_LARYNX_EXALLC

No definition available.

Endpoint definition

↥

Endpoint definition steps	FinnGen
Phenotype data
1. Apply sex-specific rule None	-
2. Check conditions not C3_LARYNX	-
3. Check pre-conditions, main-only, mode, registry filters Registry filters: Hospital discharge: ICD-10 — D02.0& Hospital discharge: ICD-9 — 2310 Cause of death: ICD-10 — D02.0& Cause of death: ICD-9 — 2310 Cancer registry: Topography ICD-O-3 — C32 Cancer registry: Morphology ICD-O-3 — ANY Cancer registry: Behaviour codes — 2 3 out of 7 registries used, show all original rules.	-
4. Check minimum number of events None	-
5. Include endpoints None	-
6. Filter based on genotype QC (FinnGen only) None	-

Control definitions (FinnGen only)

Control exclude: C3_CANCER, C3_CANCER_WIDE

Extra metadata

Level in the ICD hierarchy: 3
First used in FinnGen datafreeze: DF9
Parent code in ICD-10: D02
Name in latin: Carcinoma in situ bronchi

NAME	CD2_INSITU_LARYNX_EXALLC
CONTROL_EXCLUDE	C3_CANCER\|C3_CANCER_WIDE
CONTROL_PRECONDITIONS
CONTROL_CONDITIONS
SEX
INCLUDE
PRE_CONDITIONS
CONDITIONS	!C3_LARYNX
OUTPAT_ICD
OUTPAT_OPER
HD_MAINONLY
HD_ICD_10_ATC
HD_ICD_10	D020
HD_ICD_9	2310
HD_ICD_8	$!$	The FinnGen clinical team has checked and no code can be used for this rule.
HD_ICD_10_EXCL
HD_ICD_9_EXCL
HD_ICD_8_EXCL
COD_MAINONLY
COD_ICD_10	D020
COD_ICD_9	2310
COD_ICD_8	$!$	The FinnGen clinical team has checked and no code can be used for this rule.
COD_ICD_10_EXCL
COD_ICD_9_EXCL
COD_ICD_8_EXCL
OPER_NOM
OPER_HL
OPER_HP1
OPER_HP2
KELA_REIMB
KELA_REIMB_ICD
KELA_ATC_NEEDOTHER
KELA_ATC
KELA_VNRO_NEEDOTHER
KELA_VNRO
CANC_TOPO	C32
CANC_TOPO_EXCL
CANC_MORPH	ANY
CANC_MORPH_EXCL
CANC_BEHAV	2

Similar endpoints

↥

List of similar endpoints to Carcinoma in situ of larynx based on the number of shared cases.

Similar with more cases:

Similar with less cases:

Carcinoma in situ of larynx

Case counts by codes

↥

FinnGen case counts by registry codes:

No upset plot: script not run.

No upset table: script not run.

Summary Statistics

↥

-FinRegistry-

Key figures

	All	Female	Male
Number of individuals
Whole population	-	-	-
Only index persons	-	-	-
Unadjusted period prevalence (%)
Whole population	-	-	-
Only index persons	-	-	-
Median age at first event (years)
Whole population	-	-	-
Only index persons	-	-	-

-FinnGen-

Key figures

	All	Female	Male
Number of individuals	58	11	47
Unadjusted period prevalence (%)	0.02	0.00	0.02
Median age at first event (years)	64.56	38.69	70.62

-FinRegistry-

Age distribution of first events

-FinnGen-

Age distribution of first events

-FinRegistry-

Year distribution of first events

-FinnGen-

Year distribution of first events

-FinRegistry-

Cumulative Incidence Function

No data

-FinnGen-

Cumulative Incidence Function

No data

CodeWAS (R11)

↥

CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.

This is a new tool, please reach out using the contact form for feedback and improvement ideas.

First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log₁₀(p-value) ≥ 6.

Matched cohort

Matched cases
56: Matched controls
559

Code

Vocabulary

Description

Odds Ratio

-log₁₀(p)

N matched cases

N matched controls

DQB10

NOMESCO Finland

Endoscopic excision of lesion of larynx

145.3

29.3

UDQ12

NOMESCO Finland

Flexible laryngoscopy

56.5

25.8

C32.0

ICD-10 Finland

Malignant neoplasm: Glottis

+∞

24.8

D14.1

ICD-10 Finland

Benign neoplasm: Larynx

126.3

22.7

DQA10

NOMESCO Finland

Biopsy of larynx

+∞

22.4

D02.0

ICD-10 Finland

Carcinoma in situ: Larynx

+∞

20.0

8070/2-C32.0

ICD-O-3

Squamous cell carcinoma in situ, NOS, of glottis

+∞

18.8

D38.0

ICD-10 Finland

Neoplasm of uncertain or unknown behaviour: Larynx

+∞

17.6

C320, 8077, 2

ICD-O-3

+∞

15.3

130

Kela drug reimbursment

Malignant tumour

+∞

14.1

J37.0

ICD-10 Finland

Chronic laryngitis

39.6

13.9

J38.3

ICD-10 Finland

Other diseases of vocal cords

91.2

13.3

ZXC10

NOMESCO Finland

Use of laser

36.4

12.9

WF002

NOMESCO Finland

Radical radiotherapy

+∞

11.9

C61

ICD-10 Finland

Malignant neoplasm of prostate

+∞

9.6

A03FA01

ATC

metoclopramide; systemic, rectal

13.0

9.6

UDQ22

NOMESCO Finland

Microlaryngoscopy

29.8

9.4

EP1AE

NOMESCO Finland

Neck ultrasound examination

20.6

9.1

8140/3-C61.9

ICD-O-3

Adenocarcinoma, NOS, of prostate gland

+∞

8.5

WZC00

NOMESCO Finland

Planning of intervention or health care consultation

5.5

7.7

2310A

ICD-9 Finland

Carcinoma in situ of respiratory system, Larynx

+∞

7.4

C32.9

ICD-10 Finland

Malignant neoplasm: Larynx, unspecified

+∞

7.4

UDH02

NOMESCO Finland

Rhinopharyngoscopy

16.7

7.2

WX404

NOMESCO Finland

Intravenous generell anesthesy

5.9

7.2

XX3DW

NOMESCO Finland

Time consuming IT work

13.3

6.6

WF003

NOMESCO Finland

Adjuvant radiotherapy

+∞

6.4

WZC20

NOMESCO Finland

Multidisciplinary treatment meeting

+∞

6.4

8070/2-C32.9

ICD-O-3

Squamous cell carcinoma in situ, NOS, of larynx, NOS

+∞

6.4

GD1BD

NOMESCO Finland

Thorax extensive CT-examination

13.2

6.1

LabWAS

↥

(ID) Name

N Cases

N Controls

-log₁₀(p)

cases

controls

unit

cases

controls

-log₁₀(p)

N cases

N controls

(40768804) Tissue Pathology biopsy report

112

5.52

9.66

4.0

1.5

—

(4035726)

10.21

8.76

1.7

1.2

—

(3032080) INR in Blood by Coagulation assay

190

3.36

4.78

11.8

10.9

inr

1.3

0.07

(3001079) Blood group antibody screen [Presence] in Serum or Plasma

167

2.84

3.70

5.0

3.5

—

(3013512) EKG study

143

2.85

3.70

7.4

4.4

—

(3037467) Urinalysis macro (dipstick) panel - Urine

278

3.11

3.61

5.1

3.9

—

(3023368) Bacteria identified in Blood by Culture

129

2.84

3.60

5.4

4.1

—

(3019225) pH of Specimen

3.72

3.44

2.7

3.1

—

(3044640) Blood type and Crossmatch panel - Blood

117

2.79

3.41

3.2

2.2

—

(3042936) Bacteria identified in Isolate by Culture

3.07

3.21

1.9

1.7

—

(3007853) Bacteria identified in Skin by Aerobe culture

3.00

2.66

1.8

2.1

—

(3019800) Troponin T.cardiac [Mass/volume] in Serum or Plasma

207

2.38

2.62

5.8

4.0

ng/l

76.1

67.3

0.08

159

(3002256) Pathology report gross observation

3.75

2.52

1.4

1.1

—

(3027945) Reticulocytes/100 erythrocytes in Blood

2.71

2.37

2.4

1.6

1.5

0.14

(3012095) Magnesium [Moles/volume] in Serum or Plasma

2.63

2.36

4.7

3.0

mmol/l

0.8

0.07

(586526) SARS-CoV-2 (COVID-19) RNA [Presence] in Nasopharynx by NAA with probe detection

3.24

2.18

1.6

1.5

—

(40761536) Microorganisms panel - Urine sediment

3.24

2.18

4.6

3.1

—

(3024403) Complement+Immunoglobulin [Units/volume] in Red Blood Cells

5.35

2.11

1.2

1.4

—

(3044938) Influenza virus A RNA [Presence] in Specimen by NAA with probe detection

2.60

2.09

2.8

2.0

—

(3020630) Protein [Mass/volume] in Serum or Plasma

2.89

2.04

1.9

2.5

g/l

68.2

66.5

—

(3043924) Respiratory syncytial virus RNA [Identifier] in Specimen by NAA with probe detection

2.74

1.87

1.9

—

(706163) SARS-CoV-2 (COVID-19) RNA [Presence] in Respiratory system specimen by NAA with probe detection

192

2.02

1.83

2.4

2.3

—

(40764999) Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI)

399

2.47

1.82

25.0

13.0

ml/min/173m2

73.7

73.3

0.04

319

(3019902) Methicillin resistant Staphylococcus aureus [Presence] in Specimen by Organism specific culture

2.54

1.76

7.4

3.3

—

(3029287) Urinalysis microscopic panel [#/volume] - Urine by Automated count

160

1.99

1.70

3.9

3.0

—

(40760892) CBC W Ordered Manual Differential panel - Blood

2.29

1.64

4.1

5.4

—

(3021601) Nitrite [Presence] in Urine by Test strip

190

1.92

1.59

3.6

4.8

estimate

0.0

—

(3035350) Ketones [Presence] in Urine by Test strip

190

1.92

1.59

2.9

3.5

estimate

0.0

—

(3004119) Hemoglobin [Mass/volume] in Venous blood

2.80

1.57

2.6

2.5

g/l

134.9

124.6

—

(3004588) Protein electrophoresis panel - Serum or Plasma

2.69

1.56

1.9

1.2

—

(3014162) Mycobacterium tuberculosis DNA [Presence] in Specimen by NAA with probe detection

3.54

1.55

1.4

4.2

—

(3020564) Creatinine [Moles/volume] in Serum or Plasma

450

2.50

1.53

31.5

16.8

umol/l

92.1

87.9

0.19

450

(3013826) Glucose [Moles/volume] in Serum or Plasma

258

1.90

1.53

5.7

4.9

mmol/l

7.8

7.1

0.50

238

(3009261) Glucose [Presence] in Urine by Test strip

193

1.87

1.49

3.0

3.5

estimate

0.0

—

(42870588) Differential panel, method unspecified - Blood

140

1.92

1.49

6.3

5.6

—

(3000494) Fungus identified in Specimen by Culture

2.47

1.48

1.2

1.5

—

(3005719) IgG [Mass/volume] in Serum or Plasma

2.92

1.47

1.8

2.2

g/l

10.1

10.8

—

(3027273) Bicarbonate [Moles/volume] in Venous blood

2.92

1.47

2.8

2.9

mmol/l

27.6

25.0

—

(3022313) Gas panel - Capillary blood

2.92

1.47

3.3

2.5

—

(3005772) Bilirubin.conjugated [Moles/volume] in Serum or Plasma

2.41

1.45

1.8

3.7

umol/l

25.7

6.5

—

(3048816) Calcium.ionized [Moles/volume] adjusted to pH 7.4 in Blood

2.60

1.44

5.4

4.3

mmol/l

1.2

—

(3038288) Influenza virus B RNA [Presence] in Specimen by NAA with probe detection

2.35

1.41

2.2

2.0

—

(40761511) CBC panel - Blood by Automated count

451

2.48

1.38

27.0

12.9

—

(3000492) Spirometry study

2.56

1.35

2.1

1.6

—

(3017143) Hepatitis C virus Ab [Presence] in Serum

2.67

1.34

1.0

1.5

—

(3010517) Carboxyhemoglobin/Hemoglobin.total in Venous blood

2.78

1.24

2.6

1.8

2.0

1.0

—

(3024889) Methemoglobin/Hemoglobin.total in Venous blood

2.78

1.24

2.6

1.8

0.7

0.5

—

(3007930) Methemoglobin/Hemoglobin.total in Blood

2.78

1.24

4.2

4.4

1.0

0.9

—

(3044889) 12 lead EKG panel

309

1.80

1.24

4.5

—

(3041096) Erythrocytes [Presence] in Urine by Automated

106

1.85

1.20

3.9

3.1

—

(3023081) Carboxyhemoglobin/Hemoglobin.total in Blood

2.64

1.17

4.2

4.3

1.3

1.6

—

(3013707) Erythrocyte sedimentation rate by Westergren method

312

1.76

1.17

4.8

3.9

mm/h

15.7

12.2

0.47

283

(3029937) Albumin [Presence] in Urine by Test strip

109

1.79

1.09

3.5

3.6

estimate

0.0

—

(3002032) Base excess in Venous blood by calculation

2.03

1.06

3.3

3.2

mmol/l

3.0

2.0

—

(3013603) Prostate specific Ag [Mass/volume] in Serum or Plasma

286

1.68

1.06

6.5

4.1

ug/l

1.6

2.2

1.01

252

(46236098) ABO and Rh group [Type] in Blood by Confirmatory method

1.85

1.06

3.9

2.1

—

(43054903) Holo-transcobalamin II [Moles/volume] in Serum

190

1.67

1.06

2.2

2.0

pmol/l

98.9

89.0

0.85

103

(3020682) Albumin/Creatinine [Ratio] in Urine

159

1.62

0.91

4.5

4.4

mg/mmol

2.4

10.5

1.95

104

(40763086) Leukocyte esterase [Presence] in Urine by Automated test strip

151

1.61

0.88

3.5

3.6

—

(36304419) Bacteria [Presence] in Urine

117

1.64

0.84

5.2

2.6

—

(3026008) Bacteria identified in Urine by Culture

118

1.62

0.81

2.9

—

(3000330) Specific gravity of Urine by Test strip

2.28

0.78

2.0

4.7

—

(36031861) Influenza virus A and B and SARS-CoV-2 (COVID-19) and Respiratory syncytial virus RNA panel - Respiratory system specimen by NAA with probe detection

2.18

0.76

2.4

1.8

—

(3028286) Albumin [Mass/volume] in Serum or Plasma by Electrophoresis

2.09

0.74

2.4

1.0

g/l

43.1

37.6

—

(3019060) Gas panel - Arterial blood

1.85

0.74

2.3

4.2

—

(3015736) pH of Urine

148

1.54

0.73

2.7

3.5

—

(3015399) Transferrin receptor.soluble [Mass/volume] in Serum or Plasma

104

1.60

0.71

2.1

2.0

mg/l

2.5

2.9

0.31

(3019284) Hepatitis B virus surface Ag [Presence] in Serum

1.93

0.70

1.0

1.3

—

(3009542) Hematocrit [Volume Fraction] of Blood

356

1.52

0.68

21.8

14.7

39.3

39.4

0.03

228

(3015322) Alpha 1 globulin [Mass/volume] in Serum or Plasma by Electrophoresis

1.73

0.63

2.4

1.1

g/l

2.6

3.1

—

(3012516) Albumin [Mass/volume] in Urine

153

1.47

0.62

3.1

3.3

mg/l

60.4

86.5

0.20

(3020961) Endomysium IgA Ab [Titer] in Serum

0.00

0.61

0.0

1.1

—

(3018418) pH of Serum or Plasma

121

1.45

0.51

6.0

4.2

7.4

—

(3043747) Beta 2 globulin [Mass/volume] in Serum or Plasma by Electrophoresis

1.67

0.44

2.4

1.1

g/l

3.7

3.9

—

(3043723) Beta 1 globulin [Mass/volume] in Serum or Plasma by Electrophoresis

1.67

0.44

2.4

1.1

—

(3005229) Alpha 2 globulin [Mass/volume] in Serum or Plasma by Electrophoresis

1.67

0.44

2.4

1.1

g/l

6.8

7.8

—

(3033319) Streptococcus pyogenes Ag [Presence] in Throat

0.00

0.42

0.0

1.1

—

(3003031) Transferrin.carbohydrate deficient.disialo/Transferrin.total in Serum or Plasma

1.51

0.41

1.0

1.9

1.5

2.5

—

(4034850)

0.00

0.41

0.0

15.9

—

(3024135) Streptococcus.beta-hemolytic [Presence] in Throat by Organism specific culture

1.47

0.40

1.0

1.3

—

(40758558) Short blood count panel - Blood

1.42

0.40

9.3

5.3

—

(3000991) Gas panel - Venous blood

1.42

0.39

3.0

9.0

—

(3005785) Creatine kinase.MB [Mass/volume] in Serum or Plasma

1.34

0.30

1.6

2.2

ug/l

4.3

9.0

—

(3004789) Transferrin [Mass/volume] in Serum or Plasma

1.31

0.29

1.9

2.9

g/l

2.3

2.1

—

(3005013) Prostate Specific Ag Free [Mass/volume] in Serum or Plasma

156

0.79

0.25

3.2

2.9

ug/l

0.8

—

115

(3020779) Urea [Moles/volume] in Serum or Plasma

1.38

0.24

3.0

8.5

mmol/l

9.9

11.4

—

(40761535) Cells panel - Urine sediment

1.34

0.24

1.2

2.9

—

(3019832) Treponema pallidum Ab [Presence] in Serum

0.00

0.21

0.0

1.5

—

(3048929) Epstein Barr virus Ab [Presence] in Serum

0.00

0.21

0.0

1.2

—

(3039443) Prostate specific Ag panel - Serum or Plasma

0.00

0.21

0.0

1.5

—

(3046870) Tissue transglutaminase IgG Ab [Units/volume] in Serum

0.00

0.21

0.0

1.0

—

(3044491) Cholesterol non HDL [Mass/volume] in Serum or Plasma

0.00

0.21

0.0

1.6

—

(3010521) Mycoplasma pneumoniae IgM Ab [Presence] in Serum by Immunoassay

0.00

0.21

0.0

1.1

—

(3027450) Sjogrens syndrome-B extractable nuclear Ab [Units/volume] in Serum

0.00

0.21

0.0

1.2

—

(3036086) Jo-1 extractable nuclear Ab [Units/volume] in Serum by Immunoassay

0.00

0.21

0.0

1.2

—

(3025245) SCL-70 extractable nuclear Ab [Units/volume] in Serum by Immunoassay

0.00

0.21

0.0

1.1

—

(3007220) Creatine kinase [Enzymatic activity/volume] in Serum or Plasma

160

1.18

0.16

3.5

2.1

u/l

303.0

245.9

0.17

147

(3001784) Prostate Specific Ag Free/Prostate specific Ag.total in Serum or Plasma

221

0.85

0.16

6.8

3.7

23.1

24.8

—

116

(3003694) ABO and Rh group [Type] in Blood

1.23

0.16

1.9

1.3

—

(3002385) Erythrocyte distribution width [Ratio]

340

1.16

0.15

31.1

16.8

14.1

13.8

1.04

333

(1761868) Lipid panel - Serum or Plasma

143

1.16

0.13

4.1

3.5

—

(3022948) Iron [Moles/volume] in Serum or Plasma

1.11

0.08

2.0

2.7

umol/l

9.3

12.2

—

(3001122) Ferritin [Mass/volume] in Serum or Plasma

164

1.05

0.00

3.6

2.7

ug/l

193.2

164.5

0.18

147

(1001926) Buprenorphine [Presence] in Urine by Screen method

0.00

0.0

1.0

—

(3027944) Amphetamines [Presence] in Urine

0.00

0.0

1.0

—

(3027008) Opiates [Presence] in Urine

0.00

0.0

1.0

—

(3028300) Cannabinoids [Presence] in Urine

0.00

0.0

1.0

—

(3029511) Human papilloma virus DNA [Presence] in Specimen by NAA with probe detection

0.00

0.0

1.2

—

(36032419) SARS-CoV-2 (COVID-19) Ag [Presence] in Upper respiratory specimen by Immunoassay

0.00

0.0

1.3

—

(3045783) Sodium and Potassium panel [Moles/volume] - Serum or Plasma

0.93

0.00

3.8

7.2

—

(40759040) C peptide [Moles/volume] in Serum or Plasma --post meal

0.00

0.0

1.2

—

2.3

—

(3016879) Cocaine [Presence] in Urine

0.00

0.0

1.0

—

(3004616) Nuclear Ab [Presence] in Serum

0.00

0.0

1.0

—

(3000012) Reticulocyte production index

0.00

0.0

2.2

—

(44816559) Phosphatidylethanol [Mass/volume] in Blood

0.00

0.0

1.0

—

(3027545) Mycoplasma pneumoniae Ab [Presence] in Serum by Immunoassay

0.00

0.0

1.5

—

(3045788) Cell count panel - Pleural fluid

0.00

0.0

1.0

—

(3014973) Borrelia burgdorferi IgM Ab [Units/volume] in Cerebral spinal fluid

0.00

0.0

1.2

—

(40762119) U1 small nuclear ribonucleoprotein 70kD Ab [Units/volume] in Serum

0.00

0.0

1.0

—

(3028369) Herpes simplex virus 1+2 DNA [Presence] in Specimen by NAA with probe detection

0.00

0.0

1.2

—

(3000764) Benzodiazepines [Presence] in Urine

0.00

0.0

1.0

—

(3007368) IgG [Mass/volume] in Cerebral spinal fluid

0.00

0.0

1.2

—

49.8

—

(3047007) Chlamydophila sp Ab [Presence] in Serum

0.00

0.0

1.1

—

(40768806) Pleura Pathology biopsy report

0.00

0.0

1.2

—

(3006093) Chlamydia trachomatis DNA [Presence] in Specimen by NAA with probe detection

0.00

0.0

2.0

—

(3010380) Borrelia burgdorferi IgG Ab [Units/volume] in Cerebral spinal fluid

0.00

0.0

1.2

—

(21494890) Protein electrophoresis panel - 24 hour Urine

0.00

0.0

1.0

—

(1175715) Chlamydophila pneumoniae IgM Ab [Presence] in Serum by Immunoassay

0.00

0.0

1.3

—

(40768797) Stomach Pathology biopsy report

0.92

0.00

1.8

1.1

—

(3039162) Centromere protein B Ab [Units/volume] in Serum

0.00

0.0

1.1

—

(3041145) Herpes simplex virus IgM Ab [Presence] in Serum by Immunoassay

0.00

0.0

1.0

—

(3012447) Hantavirus puumala IgG Ab [Titer] in Serum

0.00

0.0

1.0

—

(3011397) Hemoglobin [Presence] in Urine by Test strip

1.00

0.00

1.6

3.6

—

(3012441) Differential panel - Pleural fluid

0.00

0.0

1.0

—

(36033641) SARS-CoV-2 (COVID-19) Ag [Presence] in Upper respiratory specimen by Rapid immunoassay

0.00

0.0

1.2

—

(3007844) Epstein Barr virus capsid IgM Ab [Units/volume] in Serum by Immunoassay

0.00

0.0

1.1

—

(40760848) Basement membrane zone BP180 Ab [Units/volume] in Serum by Immunoassay

0.00

0.0

1.3

—

(42868544) Hantavirus puumala IgM Ab [Presence] in Serum or Plasma by Immunofluorescence

0.00

0.0

1.0

—

Mortality – FinRegistry

↥

Association

Association between endpoint CD2_INSITU_LARYNX_EXALLC and mortality.

Females

No data

Males

No data

Mortality risk

Mortality risk for people of age

years, who have CD2_INSITU_LARYNX_EXALLC.

N-year risk	Females	Males
1	No data	No data
5	No data	No data
10	No data	No data
15	No data	No data
20	No data	No data

Relationships between endpoints

↥

Index endpoint: CD2_INSITU_LARYNX_EXALLC – Carcinoma in situ of larynx

GWS hits: -

Endpoint

Case Overlap

Survival Analysis

Genetic Correlations

Genetic Signals

N (Jaccard index)

HR [CI]

Extremity

rg [CI]

Extremity

Hits

Coloc Hits

FinRegistry

FinnGen

FinRegistry

FinnGen

Loading data

Carcinoma in situ of larynx

Endpoint definition

Endpoint definition steps

FinnGen

Phenotype data

1. Apply sex-specific rule

2. Check conditions

3. Check pre-conditions, main-only, mode, registry filters

4. Check minimum number of events

5. Include endpoints

6. Filter based on genotype QC (FinnGen only)

Similar endpoints

Case counts by codes

Summary Statistics

-FinRegistry-

Key figures

-FinnGen-

Key figures

-FinRegistry-

Age distribution of first events

-FinnGen-

Age distribution of first events

-FinRegistry-

Year distribution of first events

-FinnGen-

Year distribution of first events

-FinRegistry-

Cumulative Incidence Function

-FinnGen-

Cumulative Incidence Function

CodeWAS (R11)

Matched cohort

LabWAS

Mortality – FinRegistry

Association

Females

Males

Mortality risk

Relationships between endpoints